Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
49.57(c) 49.68(c) 49.8(c) 48.78(c) 48.21 Last
767 265 1 119 036 585 873 911 319 468 318 Volume
-2.40% +0.22% +0.24% -2.05% -1.17% Change
More quotes
Financials (USD)
Sales 2018 520 M
EBIT 2018 -239 M
Net income 2018 -228 M
Finance 2018 673 M
Yield 2018 -
Sales 2019 739 M
EBIT 2019 -83,5 M
Net income 2019 -71,1 M
Finance 2019 701 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 13,8x
EV / Sales2019 9,71x
Capitalization 7 876 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer.Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
04/19SEATTLE GENETICS : Highlights Novel Antibody-Drug Conjugate Technologies and Imm..
AQ
04/17SEATTLE GENETICS : Highlights Novel Antibody-Drug Conjugate Technologies and Imm..
AQ
04/16SEATTLE GENETICS : Highlights Novel Antibody-Drug Conjugate Technologies and Imm..
AQ
04/12SEATTLE GENETICS : Highlights Novel Antibody-Drug Conjugate Technologies and Imm..
BU
04/10SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of First Quart..
AQ
04/05SEATTLE GENETICS : and Astellas Receive FDA Breakthrough Therapy Designation for..
AQ
04/05SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of First Quart..
BU
04/01SEATTLE GENETICS : U.S. Patents Awarded to Inventors in California (April 1)
AQ
03/29SEATTLE GENETICS : Announces FDA Approval of ADCETRIS® Brentuximab Vedotin in Co..
AQ
03/28SEATTLE GENETICS : FDA approves revolutionary blood cancer treatment
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03:38a$WINT, $SGEN - Windtree Therapeutics #WINT vs. Seattle Genetics #SGEN Head to.. 
03:33aWindtree Therapeutics $WINT vs. Seattle Genetics $SGEN Head to Head Compariso.. 
04/24Seattle Genetics searches for its 10th building to keep up with growth  
04/24Seattle Genetics $SGEN Set to Announce Quarterly Earnings on Wednesday  
04/23Seattle Genetics $SGEN Lifted to Hold at Zacks Investment Research  
More tweets
Qtime:120
News from SeekingAlpha
04/24JF'S CORE BIOTECH BUYS #12 : Updates And Introducing Our 18th Selection 
04/20Key events next week - healthcare 
04/19Premarket analyst action - healthcare 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
04/10JF'S CORE BIOTECH BUYS #10 : Incyte Disappoints, Optimism Returns To Gene Therap.. 
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 66,0 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technical Officer
Srinivas Akkaraju Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.-6.92%7 876
CELLTRION, INC.--.--%31 379
IQVIA HOLDINGS INC-1.18%20 258
LONZA GROUP-7.06%18 717
INCYTE CORPORATION-34.17%14 493
NEKTAR THERAPEUTICS43.08%13 873